The purpose of this study was to evaluate the value of phosphorylated tau with epitopes threonine 181(p-tau181) in cerebrospinal fluid (CSF) for the differential diagnosis of Alzheimer's disease typed dementia from other type of dementia. Methods: A systematic literature search was performed to identify studies on p-tau181. Two evaluators independently evaluated the quality of the ten studies using the Scottish Intercollegiate Guidelines Network (SIGN) tool. The literature review covered from October 27, 1946 to October 22, 2013, and eight domestic databases including KoreaMed and international databases including Ovid-MEDLINE, EMBASE, and Cochrane Library were used. Tau concentrations were compared to healthy controls and to subjects with Alzheimer's disease (AD) using random effect metaanalysis. Outcome measures were Cohen's delta, sensitivity and specificity. Results: Finally, 8 studies (8 diagnostic evaluation studies) were identified to evaluate CSF p-tau181. The effectiveness of this test was evaluated based on diagnostic accuracy. The diagnostic accuracy for identifying AD by ELISA was high which revealed pooled sensitivity as 0.843 (95% CI 0.818-0.867), pooled specificity as 0.799(95% CI 0.768-0.828) and summary receiver operating characteristic area under the curve 0.9082 ± 0.0236. Conclusions: CSF p-tau181 concentrations in other type of dementia are intermediate between controls and AD patients. Overlap between both controls and AD patients results in insufficient diagnostic accuracy, and the development of more specific biomarkers for these disorders is needed.
INTRODUCTION
Dementia is now becoming huge social problem and Alzheimer' s disease (AD) is the most common type of dementia among various types of it [1] . So, suitable strategies for diagnosis, treatment and prevention for AD are very important.
Recent revised diagnostic criteria for AD by the National Institute on Aging and the Alzheimer Association broaden the spectrum of AD from dementia phase to preclinical and predementia phase [2] . After successive failures of large scale clinical therapeutic trials focused on AD dementia, many researchers insisted on moving to early stage of disease such as preclinical or pre-dementia stage for the initiation of AD therapeutics [3, 4] . To perform this, the early diagnosis of AD is essential and the biomarkers play a great role in those fields [5] . AD biomarkers might be grouped into two categories http://dx.doi.org/10.12779/dnd.2014.13.4.129 www.dementia.or.kr based on the biologic viewpoint. They are biomarkers of amyloid-beta (Aβ) depositions measured using cerebrospinal (CSF) Aβ or amyloid PET imaging, and neuronal degeneration measured using CSF tau, 18 fluorodeoxyglucose (FDG)
PET or structural MRI [6] . Among these various biomarkers, those based on CSF reflect essential neuropathology characteristics of AD such as amyloid plaque and neurofibrillary tangles and [7] and these pathologic changes precede clinical onset of dementia by more than 20 years. Therefore, CSF biomarkers are appropriate candidate for very early diagnosis of AD. Because tau pathology such as neurofibrillary tangle was found in the entorhinal cortex of early stage of AD patient [8] , a tau protein regarded as promising candidate for biomarker that could be used in clinical practice. And most studies suggested that phosphorylated tau (p-tau) had much more specificity than total tau (t-tau) for the diagnosis of AD. Recent immunoassays can measure the phosphorylated epitope of threonine 181 (p-tau181), serine 199 (p-tau199), threonine 231 (ptau231) or combination of them. Among these subtypes of ptau, p-tau181 is approved for clinical practice in Korea and different tau epitopes had similar values, showing no significant difference among them [9] . To evaluate the clinical value of ptau181 in CSF for the differential diagnosis of AD, we aimed to integrate studies which have studied p-tau181. We are to evaluate the difference between AD versus other dementia, AD versus subject with normal cognition and amnestic mild cognitive impairment (MCI) versus non-amnestic MCI using systemic review of literature and meta-analysis.
METHODS

Search strategy
We conducted a systematic review on the eight Korean da- 
Inclusion and exclusion criteria
The searches included in Korean and English. It had to fulfill criteria for study quality: a prospective cohort (including case-cohort or nested case-control designs); measurement of the relevant p-tau; a study reporting the relative risk or equivalent effect estimates for incident AD, and/or mean differences in cognitive decline for studies of that outcome should have at least follow-up duration; and be adjusted for age at a minimum.
We excluded animal or preclinical studies and non-systematic reviews, editorial, letter, comment, opinion pieces, review, congress or conference material, guideline, note, news article, and abstract.
Study selection
After the initial keyword search, there were 496 results from MEDLINE, 957 from EMBASE, and 0 from domestic database for a total of 1,453 studies. There were also 1 manual-searched domestic and 49 foreign studies. We excluded duplicated documents, those about animal study or preclinical studies which was not written in English or Korean. As a result, 203 studies were identified for the further consideration. After two investigators independently reviewed the remaining articles and performed the first stage of selection. Finally, eight studies that met all of our inclusion criteria remained ( Fig. 1 ).
Level of evidence in the literature
Studies were evaluated using the Methodology Checklist (Table 3) .
Data extraction
The variables were extracted from each study by two independent investigators. They were consisted of diagnosis; year of publication; study design; name of cohort, exposures measured, and variable coding methods; outcomes measured; length of follow-up; sample size; demographics (mean age at baseline, sex, and ethnicity); effect measures, respective P values and confidence intervals, and/or standard errors; number of cases in each group; and covariates used in modeling; country of study population. Selection and categorization were performed in other researchers. The data were then categorized according to the type of data, study characteristics, and the reliability of the techniques employed.
Final extraction of data from validated primary sources was performed by two evaluators.
Statistical anaylyses
Chi-square (χ 
RESULTS
Included and excluded studies
The 1,503 studies including 50 with manual search were identified. Among them, 444 studies were overlapping documents and a total of 856 were excluded according to the exclusion criteria described above. On top of that, studies with inappropriate method (n = 13), those without p-tau analysis A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results B A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+ C A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++ D Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+
RCT, a randomized controlled trial. 
1++
• High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1+
• Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1-
• Meta-analyses, systematic reviews, or RCTs with a high risk of bias 2++
• High quality systematic reviews of case control or cohort or studies • High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal 2+
• Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal 2-
• Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal 3
• Non-analytic studies, e.g. case reports, case series 4
• were also excluded. Finally, 8 studies were selected for this study ( Fig. 1 ) [10] [11] [12] [13] [14] [15] [16] [17] [18] . The basic information of these studies were described in Table 4 .
Systemic review of literature
Amnestic mild cognitive impairment (aMCI) versus non amnestic mild cognitive impairment (naMCI)
According to systemic review about clinical value of p-tau181 was 48.6± 23.65-100± 25 pg/mL for aMCI and 38.5± 8.4-70.0 ± 27.0 pg/mL for naMCI [15, 17] . The prediction of conversion from aMCI to AD was reported by 1 study as 40.0%. The diagnostic accuracy was 0.51-0.87 for the sensitivity and 0.33-0.79 for the specificity (Table 4 ).
Alzheimer' s disease versus healthy subjects
Clinical values of p-tau181 was described in 6 studies as 63.5 ± 40.3-98.0± 25 pg/mL for AD and 24.8± 5.9-46.5± 9 pg/mL for healthy subjects. The diagnostic accuracy was 0.74-1.00
for the sensitivity and 0.65-0.91 for the specificity (Table 4 ).
Alzheimer' s disease versus other dementia
Clinical values of p-tau181 was described in 8 studies as 63.5 ± 40.3-98.0 ± 25 pg/mL for AD and 18.8 ± 6.7-51 ± 45.0 pg/ mL for healthy subjects. The diagnostic accuracy was 0.77-0.86
for the sensitivity and 0.42-0.96 for the specificity (Table 4) .
Comparing 95% confidence interval of each clinical group using mean value and standard deviation, the values of ptau181 in healthy subjects was overlapped with those of other clinical groups as well as diseased group themselves (Fig. 2) 
Meta-analysis
The funnel plot to confirm the publication bias is shown in Fig. 3 . (Fig. 4 ).
Alzheimer' s disease versus healthy subjects
The p-tau181 concentration of CSF is increased in AD compared to healthy subjects but heterogeneity was very high (Fig. 4) .
Alzheimer' s disease versus other dementia
The p-tau181 concentration of CSF is decreased by 42.24 pg/ mL in the other dementia compared to AD but heterogeneity was high (I 2 = 61%) ( Table 5 (Fig. 4) .
DISCUSSION
The purpose of this study is to evaluate the value of the ptau181 in CSF for the differential diagnosis of AD from other type of dementia as well as from normal control. It is somewhat controversial concerning the usability or cut-off value of the CSF p-tau because there was some discrepancy according to previous reports and it might be derived from the variability of sample acquisition, processing or repository method [19] . There are already reported well-organized meta-analysis for CSF p-tau and meta-review for all CSF biomarker of AD [9, 20] but they did not focus on the CSF p-tau181 which is clinically available in Korea. So, we tried to focus on the evaluation of it. Eight analyses were previously reported regarding the value of CSF p-tau181 concentration as a biomarker of AD, MCI or other dementia. CSF p-tau181 showed good differentiation between AD versus healthy subject. According to our meta-analysis, discrimination was revealed by sensitivity and specificity value of 84.4% and 76.9%, respectively and there was some difference of the value of previously reported one by 77.6% and 87.9% [20] although it was about p-tau regardless of its epitope (p181, p199 or p231). The CSF p-tau181 also showed good differentiation between AD and other dementia represented by sensitivity and specificity value of 84.3% and 79.9%. The development of more specific biomarkers for these disorders is needed because some study suggested that biomarker of AD should obtain sensitivity and specificity of 75-80% or greater [21] .
According to the systemic review, CSF p-tau181 concentra- ability in cut-off values for CSF biomarker [9] . Recently new methodologies have been reported to reduce the inter-and intra-assay variability compared to conventional method such as ELISA [22] . Standardization processes are essential to get validity in the result of CSF biomarker, but it is not achieved at present so some suggestions such as proposed normalized index or systemic normalization method have been reported [23, 24] . Moreover, comparison between AD and MCI was not considered in the current meta-analysis although it might be useful but still unclear.
This meta-analysis with systemic review described the ptau181 among core CSF biomarkers of AD to discriminate AD from normal healthy controls and AD from other dementia groups. Although, a large number of studies reported to validate CSF biomarkers, it is not suitable for its general application in clinical setting as diagnostic criteria [25] . The clinical diagnosis is still essential and biomarkers are complementary [2] . This study confirmed the CSF p-tau181 suitable for the discrimination of AD and normal control but showed weakness to differentiation between AD and other dementia. Because general use of CSF biomarker in clinical setting would be very important for early diagnosis as well as monitoring disease progression, the further evaluation of validity of currently accepted tool such as CSF p-tau might be useful.
